Introduction
Hepatitis C virus (HCV) coinfection is a leading cause of morbidity and mortality among HIV-infected individuals [1] . Newer HCV therapies utilizing HCV protease inhibitors were licensed for the treatment of HCV monoinfection in the United States and Europe in 2011 [2] . Phase 2 clinical trials in HIV/HCV coinfected patients demonstrate sustained virologic response rates as high as 74% in those with HCV genotype 1 infection [3, 4] . Clinical trial results for oral interferon (IFN)-free regimens for HCV monoinfected patients have been presented at national conferences, and the first IFN-free regimen for the treatment of HCV genotypes 2 and 3 in HCV monoinfected patients was submitted to the US Food and Drug Administration (FDA) in April 2013 [5] . These regimens attain 90% or greater SVR, with little toxicity and only 12 weeks of therapy [6] [7] [8] [9] .
The improved efficacy and toxicity profiles of new treatments are accompanied by higher costs [1, 10, 11] . Because many HIV/HCV coinfected patients rely on publicly funded health insurance (or other public payers such as the prison healthcare system), treatment for HIV/HCV coinfection often occurs in resource-constrained settings [12] . In such environments, efficient use of HCV therapy could increase the number of people treated for HCV, maximizing the population-level benefits of HCV treatment.
Genome-wide association studies have discovered that those with homozygosity at a single nucleotide polymorphism (rs12979860) related to the interleukin-28 beta subunit (IL28B) gene, the 'CC' genotype, have better treatment response to pegylated interferon (PEG) and ribavirin (RBV) than those with non-CC genotypes [13] [14] [15] [16] . Using IL28B to triage CC genotype patients to initiate PEG/RBV without an HCV protease inhibitor could control costs. Another potential strategy is to initiate all patients on PEG/RBV, adding an HCV protease inhibitor only for those who experience virologic failure. The comparative effectiveness and cost-effectiveness of such approaches in HIV/HCV coinfection are unknown.
To inform strategies for use of new therapies for HIV/ HCV coinfected patients, we investigated the costeffectiveness of alternative treatment options and identified approaches that would efficiently use scarce budgetary resources, potentially expanding access to HCV treatment.
Methods

Analytic overview
We used the Hepatitis C Cost-Effectiveness (HEP-CE) model, a Monte Carlo simulation of screening and treatment of HCV, to estimate the effectiveness and costeffectiveness of strategies for treating HIV/HCV coinfection. The model is summarized below and details are 366 AIDS 2014, Vol 28 available elsewhere [17] and in the supplemental materials, http://links.lww.com/QAD/A425. We considered five HCV treatment strategies ( Fig. 1 All analyses simulated a cohort of 10 million hypothetical HIV/HCV coinfected individuals chronically infected with HCV genotype 1, noncirrhotic, HCV treatmentnaive, and enrolled in US HIV guideline-concordant care. As per these guidelines, individuals were either on suppressive antiretroviral therapy (ART) or were HIV treatment-naive with CD4 þ cell count more than 500 cells/ml (Table 1) [1, 3, 6, 7, 14, 16, .
We projected outcomes including the percentage attaining SVR, life expectancy, discounted qualityadjusted life expectancy (QALE), discounted lifetime medical costs, and the incremental cost-effectiveness ratio (ICER) of each strategy compared to its next costliest alternative. We conducted one-way and multiway sensitivity analyses on these results.
We also considered scenarios using an oral, IFN-free regimen that was more effective and less toxic than PEG/RBV/TVR. We considered a range of IFN-free regimen efficacies and costs, and we identified cost/ efficacy combinations leading to IFN-free therapy having an ICER less than $100 000/quality-adjusted life year (QALY) when compared with the preferred treatment strategy without an IFN-free regimen. To explore cost-reducing strategies in cost-constrained environments, we considered scenarios similar to the base case in which patients initiate a trial of PEG/RBV, but instead of switching to triple therapy upon a failed course of PEG/RBV, they switch to IFN-free therapy.
Model structure
Hepatitis C virus disease progression
The model simulates HCV disease progression through three stages of liver disease: mild-to-moderate fibrosis, cirrhosis, and decompensated cirrhosis. Consistent with previous studies, all disease stages of HCV infection are associated with increased resource utilization and decreased quality of life (QoL) [19] [20] [21] [85] [86] [87] [88] . When individuals become cirrhotic, they are subject to increased mortality attributable to liver disease [22, 23] . With successful treatment (SVR), HCV-related mortality, resource utilization, and QoL revert to those of HIV monoinfected individuals.
HIV disease progression
We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model to estimate the cohort's HIV-related outcomes and costs [24] . CEPAC simulates HIV disease progression through CD4 þ cell count and HIV RNA levels. We used the CEPAC model to assess the cohort's progression of HIV disease across a range of CD4 þ cell and viral load categories. CEPAC provided sex-stratified estimates of monthly HIV-related mortality conditional upon being alive at the beginning of the month (life table) , mean monthly medical costs related to HIV disease, and QoL related to HIV infection. We used these CEPAC outputs as HEP-CE model inputs, such that in every month, individuals in the HEP-CE model were exposed to sex and time-dependent HIV-attribu- 'Pegylated interferon/ribavirin trial' All patients initiate the same PEG/RBV regimen as in the 'dual therapy' strategy. Those who fail to attain virologic suppression at week 4 (RVR) subsequently add TVR to their regimen for 12 weeks as described below ('triple therapy'). Patients The approach to modeling PEG/RBV therapy and the addition of TVR to failing regimens is the same as that for 'PEG/RBV trial.'
The efficacy of protease-based therapy among those who fail PEG/RBV is lower than its efficacy as first-line therapy [25] . Exposure to PEG/RBV, however, does not compromise protease efficacy if the individual simply started treatment with PEG/RBV/TVR [25] . We therefore assume that nonresponders to PEG/RBV are more likely to be nonresponders to PEG/RBV/TVR when retreated in all strategies, and we assume that in the 'PEG/RV trial' strategy, exposure of patients to PEG/RBV before adding a protease inhibitor does not reduce the overall percentage of the cohort who ultimately attain SVR.
'Triple therapy' All patients initiate a regimen of PEG/RBV/TVR for 12 weeks followed by 36 weeks of PEG/RBV alone for a 48-week total therapy course. Patients receive 750 mg three times daily of TVR in combination with the same dosage of PEG/RBV as described above. Patients undergo routine HCV RNA monitoring at treatment weeks 4 and 12. Those with HCV RNA more than 1000 copies/ml at either time point stop therapy. We did not specifically model TVR dose increases required when using efavirenz, but we effectively included such dose changes in drug cost sensitivity analyses. The approach to modeling adherence, toxicity, and therapy disutility was the same as for dual therapy, but we included rash as potential treatment toxicity.
'Interferon-free regimen' Patients initiate a 12-week course of an HCV protease inhibitor, a polymerase inhibitor, and RBV [6, 7, 26] . Compared with IFNcontaining regimens, this interferon-free regimen yields lower toxicity, higher treatment adherence, higher QoL while on therapy, and higher SVR rates. Individuals face a risk of treatment ending toxicity and nonadherence, but we assumed there are no early stopping criteria for IFN-free therapy.
Costs
We assessed costs in the model from the health system perspective. In each simulation month, individuals accrue 'background costs' associated with non-HIV/HCVrelated healthcare. In addition to these costs, there are HCV-specific and HIV-specific costs. HCV-associated costs include those of HCV medications, physician visits, laboratory tests for monitoring and safety, emergency department visits, and hospitalizations for liver-related events ( Table 1) . HIV-associated costs include costs of ART, laboratory monitoring, and hospital admissions associated with AIDS-related events [27] [28] [29] [30] [31] [32] [33] [34] [35] .
To reflect increased resource utilization among those with HIV/HCV coinfection compared with HIV monoinfection, all costs except those of HIV and HCV medications and HIV-related testing are 70% greater in coinfected individuals than in HIV monoinfected individuals [19, 36] .
Quality of life
QoL estimates include independent effects related to HIV and HCV infection integrated in the model using a multiplicative assumption [20, 21, [37] [38] [39] [40] . HIV-related QoL is a function of current CD4 þ cell count and acute AIDS-related events. HCV-related QoL is a function of fibrosis stage, HCV treatment status, and treatmentrelated toxicity ( Table 1) .
Base case parameters
The cohort was 66% male [41] [42] [43] [44] , mean age 45 years (SD 6 years) [41] [42] [43] [44] [45] , mean CD4 þ cell count 520/ml (SD 100/ml) [46] [47] [48] , and 32% IL28B CC genotype prevalent [14] ( Table 1 ). The median time to cirrhosis from HCV infection (mean age of infection 26 years [49] ) was 25 years [50] , and the rate of liver-related deaths with cirrhosis was 2.73 per 100 person-years [22, 23] .
The total SVR probability for PEG/RBV among those with CC genotype was 55% [16, [51] [52] [53] [54] and 20% for CT or TT [16, [51] [52] [53] . The total SVR probability with PEG/RBV/TVR was 74% [3] and ranged from 80 to 100% with an IFN-free regimen [6, 7] . The probability of withdrawal due to toxicity or nonadherence was 11% for triple therapy [3] , 23% for dual therapy [54] , and 3% for IFN-free therapy [6, 7] . The cost of a complete course of dual and triple therapy, including the cost of managing toxicities, was $43 000 and $87 300 respectively. The cost of a complete course of IFN-free therapy ranged from $87 300 to $175 000 [28, 30] . Those with mild-tomoderate fibrosis, cirrhosis, and decompensated cirrhosis had a QoL of 0.89, 0.62, and 0.48, respectively [20, 21, 40] .
Analyses
We calculated the ICER of each treatment strategy as the additional cost divided by the additional QALY gained compared with the next less expensive strategy [89, 90] . Strategies were considered inefficient and excluded from ICER calculations if they resulted in higher costs but fewer QALYs gained or had a higher ICER than a more effective strategy [90, 91] . QALYs and costs were both discounted at 3% annually [90] . We assumed a societal willingness-to-pay of $100 000 per QALY in which strategies below the threshold were considered 'costeffective' [92, 93] .
Results
Base case
Without HCV treatment, undiscounted life expectancy was 13.24 years, QALE was 6.76 QALYs, and discounted lifetime medical costs were $198 700 ( The 'PEG/RBV trial' strategy was the least costly approach to using an HCV protease inhibitor. 'PEG/ RBV trial' increased SVR to 72% and life expectancy and QALE compared with 'dual therapy' by 0.70 years and 1.13 QALY, a larger gain than that provided by 'dual therapy' compared with 'no treatment.' 'PEG/RBV trial' increased lifetime medical cost compared with 'dual therapy' by $42300 to $264 200, resulting in an ICER for 'PEG/RBV trial' compared with 'dual therapy' of $37 500/QALY. The 'IL28B triage' and 'triple therapy' scenarios both increased SVR by less than 1% compared with 'PEG/ RBV trial.' As a result, life expectancy and QALE increased by less than 0.01 QALY, resulting in ICERs more than $300 000/QALY ( Table 2) .
Sensitivity analysis
'PEG/RBV trial' remained the preferred (<$100 000/ QALY) treatment strategy when we varied treatment efficacy for both PEG/RBV and PEG/RBV/TVR regimens. Across all efficacy assumptions, the ICERs of 'IL28B triage' compared with 'PEG/RBV trial' and of 'triple therapy' compared with 'IL28B triage' remained more than $250 000/QALY. Total treatment costs had the greatest impact on costeffectiveness conclusions (Fig. 2) . With a higher cost of PEG/RBV therapy, the 'PEG/RBV trial' and 'dual therapy' strategies became less efficient than 'IL28B triage'. With higher PEG/RBV costs, 'triple therapy' remained economically unattractive with an ICER more than $500 000/QALY. When we reduced the cost of PEG/RBV/TVR by 50%, the 'triple therapy' strategy was most efficient, with an ICER compared to no treatment of $20 500/QALY. This remained the preferred strategy at a threshold of $100 000/QALY as long as the cost of PEG/RBV/ TVR was less than $50 000 (57% of base case cost). When we increased the cost of PEG/RBV/TVR by 50%, the 'PEG/RBV trial' strategy was preferred with an ICER of $55 600/QALY compared with 'dual therapy'. 'PEG/RBV trial' remained the preferred treatment strategy with an ICER less than $100 000/QALY across a broad range of other sensitivity analyses including HIV therapy efficacy, time to cirrhosis, QoL, and costs of routine medical care, ARTs, and laboratory tests (Fig. 2) .
Interferon-free scenario
Treating individuals with an 'IFN-free' regimen achieving 90% SVR extended discounted QALE by 2.56 years compared with no treatment, by 0.59 years compared with 'PEG/RBV trial', and by 0.57 years compared with 'triple therapy'. In a two-way sensitivity analysis comparing 'IFN-free' therapy to 'PEG/RBV trial', an IFN-free regimen that provided a 90% SVR rate had an ICER less than $100 000/QALY when the cost of the IFN-free regimen was 125% or less of the cost of a complete course of PEG/RBV/TVR, or approximately $109 000 ( Fig. 3 ). An IFN-free regimen that attained 95% SVR had an ICER less than $100 000/QALY when the cost of the IFN-free regimen was 150% or less of the cost of a complete course of PEG/RBV/TVR, or $131 000.
When we considered potential intermediate strategies using IFN-free therapy, a strategy in which all patients initiated PEG/RBVand only those with treatment failure advanced to an IFN-free regimen, was preferred with an ICER compared with 'dual therapy' of $51 800/QALY (Supplemental Table 4 , http://links.lww.com/QAD/ A425). In this scenario, providing IFN-free therapy to all patients was cost-effective (ICER <$100 000/QALY) only when the cost of a course of IFN-free treatment was less than $88 000 (base case $131 000), or when the QoL of being on PEG/RBV was less than 0.3 (similar to having compensated cirrhosis).
Discussion
We assessed the cost-effectiveness of new therapies to treat HIV/HCV genotype 1 coinfected individuals and found that although new HCV therapies improve life expectancy in coinfected patients, they substantially increase costs and are most efficiently used after an initial trial of PEG/RBV to determine protease inhibitor necessity. Furthermore, the economic efficiency of future IFN-free regimens will depend greatly on their cost. In highly costconstrained environments, initiating treatment with PEG/RBV, or using IL28B genotyping to triage patients to IFN-free therapy, may be economically attractive.
It is not surprising that we found that initiating all patients on 'triple therapy' is not cost-effective. The Re-treatment of Patients with Telaprevir-based Regimen to Optimize Outcomes (REALIZE) study demonstrates that using a Cost-effectiveness of HCV therapy in HIV coinfected patients Linas et al. 371 All costs and quality-adjusted life years (QALYs) are lifetime and discounted at an annual rate of 3%. Costs are in 2011 US dollars and rounded to the nearest $100. All life-years and QALYs are rounded to the nearest thousandth. CER, cost-effectiveness ratio; HCV, hepatitis C virus; IL28B, interleukin-28B; PEG/RBV, peginterferon and ribavirin.
lead-in of PEG/RBV before adding TVR is efficacious and does not compromise overall SVR [25] . Extrapolating this finding to naive patients, in HIV/HCV coinfected patients, there is little disadvantage to the 'PEG/RBV trial' approach, as patients who do not attain RVR with PEG/RBV alone can add TVR to their regimen without extending the treatment course or decreasing treatment efficacy. Those who attain RVR with PEG/RBV have over a 95% chance of ultimately attaining SVR [54, 94] .
Several important observations explain the greater economic efficiency of the 'PEG/RBV trial' strategy compared with 'IL28B triage'. First, the efficacy of PEG/RBV in non-CC genotypes is approximately 20%; thus, the 'IL28B triage' strategy forgoes substantial cost savings without additional clinical benefits when it assigns the 20% of patients who would have attained SVR on PEG/RBV instead to triple therapy. Second, the negative predictive value of failing to attain RVR as a predictor of attaining SVR is approximately 98% [54, 94] , whereas that of IL28B CC is only 80% [95] [96] [97] . Therefore, the 'PEG/RBV trial' strategy functions as a more specific 'diagnostic test' than IL28B testing to prioritize patients to triple therapy.
A cost-effectiveness analysis in HCV monoinfection has reported that protease inhibitor-based therapy for all HCV monoinfected patients is cost-effective when compared with the 'IL28B triage' strategy [18] . In the base case analysis, however, that study did not consider retreatment with a protease-based regimen for patients who were triaged to PEG/RBV. When the authors did consider re-treatment, the ICER of 'triple therapy' was approximately $100 000/QALY, and for some subgroups, IL28B-triage was a dominant strategy. A critical difference between HCV monoinfection and coinfection is that in monoinfection, the overall treatment course of protease-based therapy is usually 6 months, whereas that of coinfection is 12 months. As a result, strategies that assign some monoinfected patients to initiate PEG/RBV have a greater negative impact on QoL. Simultaneously, protease-based regimens are relatively less costly because using a protease inhibitor often saves the expense of 6 additional months of PEG/RBV. Thus, there may be greater disadvantage of the 'PEG/RBV trial' approach in HCV monoinfection than in HIV/HCV coinfection, in which response-guided therapy to shorten therapy is not yet proven. Finally, even in HCV monoinfection, the cost-effectiveness of initiating all patients on triple therapy is not entirely clear, as at least one costeffectiveness analysis has found that 'IL28B-triage' is preferred [98] .
In two-way sensitivity analysis, we demonstrated the range of costs and efficacies across which future IFN-free regimens would be cost-effective compared with the 'PEG/RBV trial' approach using TVR. We found that total therapy costs remained the critical factor determining cost-effectiveness. Assuming an IFN-free regimen that attains 90% SVR, treating all patients with IFN-free therapy will be cost-effective compared with proteasebased regimens only if the IFN-free regimen costs are approximately $109 000 or less.
We also explored strategies to reduce the cost of IFN-free therapy by triaging such medications to a proportion of the population. In that case, initiating PEG/RBV and advancing to IFN-free treatment for failure was the preferred strategy. Importantly, a trial of PEG/RBV was cost-effective despite the fact that in the base case scenario, QoL while taking therapy was 10 times worse for an IFN-containing regimen than for IFN-free (0.10 QALY lost vs. 0.01 QALY). Only when the QoL while taking IFN was similar to that of having decompensated cirrhosis did initiating IFN-free therapy for all patients become cost-effective.
Concern that failing an initial course of PEG/RBV could compromise the efficacy of future treatment might limit enthusiasm for the 'PEG/RBV trial' approach. Phase 2 trials of IFN-free regimens in HCV monoinfection demonstrate a lower efficacy among treatment-experienced patients [8, 9] . Such findings, however, likely demonstrate that failing PEG/RBV is a marker for having difficult to treat HCV. No data exist to suggest that firstline PEG/RBV itself decreases the efficacy of IFN-free treatment. Routine use of IFN-free regimens in budgetconstrained settings will, therefore, require price negotiations for IFN-free therapy to provide acceptable value for money compared with using those funds to treat a larger number of patients with a strategy that initiates some or all patients on PEG/RBV.
There are several limitations to this analysis. First, we based efficacy estimates for protease-based therapy on phase 2 clinical trials and developed estimates for an IFN-free regimen using trials in HCV monoinfected patients. Nonetheless, the findings that the ICERs of universal triple therapy and IFN-free therapy strategies were more than $100 000/QALY at base case therapy costs were consistent across a plausible range of efficacy assumptions. Second, many HCV providers may be inclined to treat HIV/HCV coinfected cirrhotic patients with currently available therapies, but wait for the improved toxicity profile of IFN-free regimes for patients without cirrhosis [99, 100] . Given the importance of therapy costs in determining the cost-effectiveness of treatment, it might also be economically attractive to defer HCV therapy for those with early-stage fibrosis until such time that a generic HCV protease inhibitor is available. Such questions of 'treat now or defer', though interesting, are outside the scope of this analysis, as they are critically dependent on still unknown relative efficacies of current and future therapies in early-stage and cirrhotic patients, as well as on the relative prices of multiple future drugs.
In summary, this analysis informs strategies for maximizing the population-level benefits of new HCV therapies in HIV/HCV coinfected patients. We found that in the era of 'triple therapy,' initiating PEG/RBV and adding TVR when patients fail to attain RVR or SVR maximizes the benefits attainable from constrained healthcare budgets. IFN-free regimens with improved efficacy may provide reasonable value, but this will depend on the cost of these regimens. Fig. 3 . Two-way sensitivity analysis varying costs and efficacy of interferon-free therapy as an alternative to 'peginterferon and ribavirin trial' strategy. Two-way sensitivity analysis comparing an interferon (IFN)-free regimen as an alternative to the 'peginterferon and ribavirin (PEG/RBV) trial' strategy at various cost multipliers of the base case cost of PEG/RBV/telaprevir (TVR) ($87 000 to $175 000) and efficacies [80% sustained virologic response (SVR) to 100% SVR]. The dark and light grey boxes reflect an incremental cost-effectiveness ratio (ICER) of 'IFN-free' compared with 'PEG/RBV trial' less than $50,000/QALY (dark grey) or less than $100 000/QALY (light grey), making 'IFN-free' the preferred strategy. In contrast, the black boxes reflect an ICER of 'IFN-free' compared with 'PEG/RBV trial' more than $100 000/ QALY, making 'PEG/RBV trial' the preferred strategy.
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